JP2012511322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012511322A5 JP2012511322A5 JP2011540292A JP2011540292A JP2012511322A5 JP 2012511322 A5 JP2012511322 A5 JP 2012511322A5 JP 2011540292 A JP2011540292 A JP 2011540292A JP 2011540292 A JP2011540292 A JP 2011540292A JP 2012511322 A5 JP2012511322 A5 JP 2012511322A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immunogenic composition
- antigenic ige
- linked
- ige peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 19
- 230000000890 antigenic effect Effects 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 239000002245 particle Substances 0.000 claims 11
- 239000002671 adjuvant Substances 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 229940037003 alum Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 claims 2
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 101710132601 Capsid protein Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12098908P | 2008-12-09 | 2008-12-09 | |
| US61/120,989 | 2008-12-09 | ||
| PCT/IB2009/055508 WO2010067286A2 (en) | 2008-12-09 | 2009-12-04 | IgE CH3 PEPTIDE VACCINE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012175784A Division JP5367137B2 (ja) | 2008-12-09 | 2012-08-08 | ＩｇＥＣＨ３ペプチドワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012511322A JP2012511322A (ja) | 2012-05-24 |
| JP2012511322A5 true JP2012511322A5 (enExample) | 2012-09-27 |
| JP5209800B2 JP5209800B2 (ja) | 2013-06-12 |
Family
ID=42035836
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011540292A Expired - Fee Related JP5209800B2 (ja) | 2008-12-09 | 2009-12-04 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2012175784A Expired - Fee Related JP5367137B2 (ja) | 2008-12-09 | 2012-08-08 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2013167494A Expired - Fee Related JP5964280B2 (ja) | 2008-12-09 | 2013-08-12 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2016039991A Pending JP2016164156A (ja) | 2008-12-09 | 2016-03-02 | ＩｇＥＣＨ３ペプチドワクチン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012175784A Expired - Fee Related JP5367137B2 (ja) | 2008-12-09 | 2012-08-08 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2013167494A Expired - Fee Related JP5964280B2 (ja) | 2008-12-09 | 2013-08-12 | ＩｇＥＣＨ３ペプチドワクチン |
| JP2016039991A Pending JP2016164156A (ja) | 2008-12-09 | 2016-03-02 | ＩｇＥＣＨ３ペプチドワクチン |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8298547B2 (enExample) |
| EP (2) | EP2865389A1 (enExample) |
| JP (4) | JP5209800B2 (enExample) |
| KR (3) | KR101634058B1 (enExample) |
| CN (1) | CN102245198B (enExample) |
| AR (1) | AR074505A1 (enExample) |
| AU (1) | AU2009325950B2 (enExample) |
| BR (1) | BRPI0922561A2 (enExample) |
| CA (1) | CA2744754A1 (enExample) |
| CO (1) | CO6561830A2 (enExample) |
| DK (1) | DK2376108T3 (enExample) |
| ES (1) | ES2622562T3 (enExample) |
| IL (1) | IL213029A0 (enExample) |
| MX (2) | MX337723B (enExample) |
| NZ (2) | NZ592977A (enExample) |
| PE (2) | PE20110891A1 (enExample) |
| RU (1) | RU2495049C2 (enExample) |
| SG (2) | SG186611A1 (enExample) |
| TW (1) | TWI387463B (enExample) |
| WO (1) | WO2010067286A2 (enExample) |
| ZA (1) | ZA201104072B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2594591T3 (en) * | 2005-08-11 | 2018-07-30 | Matossian Rogers Arpi | TCR-V-BETA RELATED PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASE |
| KR101329374B1 (ko) | 2008-12-09 | 2013-11-14 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 면역자극성 올리고뉴클레오타이드 |
| EP2575868A1 (en) * | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| EP2471926A3 (en) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
| JP5872684B2 (ja) * | 2011-05-26 | 2016-03-01 | インターベット インターナショナル ベー． フェー． | 免疫刺激性オリゴデオキシヌクレオチド |
| US9315814B2 (en) | 2011-05-26 | 2016-04-19 | Intervet Inc. | Immunostimulatory oligodeoxynucleotides |
| WO2013110030A2 (en) | 2012-01-19 | 2013-07-25 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
| CN104395337A (zh) * | 2012-06-18 | 2015-03-04 | 日本全药工业株式会社 | IgE肽疫苗 |
| US20170196953A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| JP6876601B2 (ja) | 2014-07-10 | 2021-05-26 | アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ | ハンチントン病の予防および／または処置における使用のための物質および方法 |
| JP6583864B2 (ja) * | 2015-09-30 | 2019-10-09 | 塩野義製薬株式会社 | 免疫賦活活性を有する核酸誘導体 |
| KR101876620B1 (ko) * | 2015-10-27 | 2018-07-09 | 대구한의대학교산학협력단 | 펩타이드 기반 분자결합자를 이용한 노로바이러스 검출칩 및 그 제작방법 |
| US11253580B2 (en) | 2016-01-07 | 2022-02-22 | Duke University | Cancer vaccines and methods of delivery |
| KR102797285B1 (ko) | 2016-03-03 | 2025-04-18 | 호유 가부시키가이샤 | 대두 알레르기의 항원 |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| SG11201908059YA (en) * | 2017-03-29 | 2019-10-30 | Shionogi & Co | Nucleic acid derivative having immunostimulatory activity |
| EP4198058A4 (en) * | 2020-08-13 | 2024-10-16 | Nibec Co., Ltd. | ANTIBODIES AGAINST INTRACELLULAR TUMOR-INDUCING PROTEIN OR FUSION PROTEIN OF A SINGLE-STRANDED VARIABLE FRAGMENT THEREOF AND CANCER CELL PENETRATING PEPTIDE AND USE THEREOF |
| US20230364232A1 (en) | 2020-09-17 | 2023-11-16 | Neovacs | IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS |
| WO2023192203A2 (en) * | 2022-03-28 | 2023-10-05 | The Regents Of The University Of California | Novel plant virus and bacteriophage vaccines |
| AU2024377259A1 (en) | 2023-11-09 | 2026-06-25 | Funpep Co., Ltd. | Vaccine composition for inducing anti-ige antibody |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1980000727A1 (en) | 1978-09-29 | 1980-04-17 | Secretary Energy Brit | Improvements in and relating to electrical power transmission in fluid wells |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| EP0092574B1 (en) | 1981-10-23 | 1992-04-29 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and methods of making same |
| US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| JPS63225397A (ja) * | 1986-10-03 | 1988-09-20 | Dainippon Pharmaceut Co Ltd | 抗アレルギー作用を有する新規ペプチド |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| NZ235315A (en) | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| US5258289A (en) * | 1990-09-05 | 1993-11-02 | Davis Claude G | Method for the selecting of genes encoding catalytic antibodies |
| EP0563091A1 (en) | 1990-12-20 | 1993-10-06 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccines based on hepatitis b surface antigen |
| SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| CN1185811A (zh) | 1995-03-31 | 1998-06-24 | H·沃尔夫 | 依赖于逆转录病毒样颗粒的抗原呈递系统 |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| TR199801722T2 (xx) | 1996-03-01 | 1998-12-21 | Novartis Ag | Peptit imm�nojenler. |
| ID18046A (id) | 1996-08-20 | 1998-02-19 | Takeda Chemical Industries Ltd | Senyawa siklik campuran, pembuatan dan penngunaannya. |
| GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| WO1998016247A1 (en) | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| WO1998055609A1 (en) | 1997-06-06 | 1998-12-10 | The Regents Of The University Of California | Inhibitors of dna immunostimulatory sequence activity |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| JP4480268B2 (ja) | 1998-02-12 | 2010-06-16 | イミューン コンプレックス コーポレイション | 戦略的修飾されたｂ型肝炎コアタンパク質及びそれらの誘導体 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6734287B1 (en) * | 1998-04-09 | 2004-05-11 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
| BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
| US7393529B2 (en) | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
| ES2234180T3 (es) * | 1998-04-09 | 2005-06-16 | Idexx Laboratories, Inc. | Proteinas de fijacion especifica para el tratamiento de la alergia canina. |
| TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| JP5329729B2 (ja) | 1998-09-03 | 2013-10-30 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 |
| US7745441B1 (en) | 1998-09-18 | 2010-06-29 | Wilex Ag | Urokinase inhibitors |
| ES2284287T3 (es) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | Sistemas adyuvantes y vacunas. |
| WO2000023955A1 (en) | 1998-10-21 | 2000-04-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Virus-like particles for the induction of autoantibodies |
| US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| DK1119630T3 (da) | 1998-11-05 | 2006-05-15 | Powderject Vaccines Inc | Nukleinsyrekonstruktioner til genetisk immunisering |
| MXPA01005389A (es) | 1998-11-30 | 2003-03-27 | Cytos Biotechnology Ag | Presentacion molecular ordenada de antigenos, metodos de preparacion y uso. |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| DE60044236D1 (de) | 1999-02-17 | 2010-06-02 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
| IL145025A0 (en) * | 1999-02-25 | 2002-06-30 | Smithkline Beecham Biolog | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses |
| US20030170229A1 (en) * | 1999-02-25 | 2003-09-11 | Smithkline Beecham Biologicals S.A. | Vaccine |
| CA2366152A1 (en) | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Streptococcus pneumoniae vaccine |
| JP2002539818A (ja) * | 1999-03-30 | 2002-11-26 | アイデックス ラボラトリーズ インコーポレイテッド | イヌのアレルギーを治療するための特異的結合蛋白 |
| DK1187629T3 (da) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| HK1049106A1 (zh) | 1999-09-24 | 2003-05-02 | Smithkline Beecham Biologicals S.A. | 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途 |
| IL148671A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| IL148844A0 (en) | 1999-09-27 | 2002-09-12 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
| JP4713809B2 (ja) | 2000-04-07 | 2011-06-29 | ユニバーシティ オブ リードズ イノベイションズ リミテッド | Ｂ型肝炎コア抗原融合タンパク質 |
| EP1278542A2 (en) | 2000-05-05 | 2003-01-29 | Cytos Biotechnology AG | Molecular antigen arrays and vaccines |
| ATE320493T1 (de) | 2000-06-22 | 2006-04-15 | Ucb Pharma Ltd | Modifizierung des hepatitis b kernantigens |
| AU2001269272A1 (en) | 2000-07-15 | 2002-01-30 | Lighthouse Display International Limited | Shelf edge display fittings |
| AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
| US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
| EP2065052A3 (en) | 2000-08-30 | 2009-08-19 | Pfizer Products Inc. | Anti-IgE vaccines |
| GB0026334D0 (en) | 2000-10-27 | 2000-12-13 | Smithkline Beecham Biolog | Vaccine |
| US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| WO2003102165A2 (en) | 2002-02-21 | 2003-12-11 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
| EP1450856B1 (en) * | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| US20040176283A1 (en) * | 2002-04-01 | 2004-09-09 | Robinson John A. | Methods and compositions for the design of synthetic vaccines |
| GB0209878D0 (en) | 2002-04-30 | 2002-06-05 | Glaxosmithkline Biolog Sa | Vaccine |
| CU22983A1 (es) * | 2002-05-08 | 2004-09-09 | Inst Finlay | Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas |
| AU2003246690B2 (en) | 2002-07-17 | 2010-03-11 | Cytos Biotechnology Ag | Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
| CA2509484C (en) | 2002-12-10 | 2012-03-20 | Lorantis Ltd. | Stabilized immunogenic hbc chimer particles |
| CN101675993A (zh) * | 2003-03-26 | 2010-03-24 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
| JP2008507474A (ja) | 2004-02-02 | 2008-03-13 | タノックス インコーポレイテッド | 新規のＩｇＥエピトープの同定 |
| JP2008506789A (ja) | 2004-07-18 | 2008-03-06 | シーエスエル、リミテッド | インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物 |
| EP1776105A2 (en) | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| GB2443591B (en) * | 2005-09-07 | 2010-04-28 | Secr Defence | Adjuvanted vaccine |
| WO2007095316A2 (en) | 2006-02-15 | 2007-08-23 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
| US20080166785A1 (en) | 2006-08-16 | 2008-07-10 | Monica Sala-Schaeffer | Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use |
| UY30994A1 (es) | 2007-04-02 | 2008-11-28 | Amgen Fremont Inc | Anticuerpos anti-ige |
| EP2158211B1 (en) * | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
| US9719791B2 (en) | 2014-12-10 | 2017-08-01 | Mapquest, Inc. | Computerized systems and methods for providing travel information and/or content to users |
| US11780237B2 (en) | 2015-06-23 | 2023-10-10 | Ripples Ltd | Method and apparatus for printing on a drink |
-
2009
- 2009-12-04 BR BRPI0922561-7A patent/BRPI0922561A2/pt not_active IP Right Cessation
- 2009-12-04 MX MX2013006964A patent/MX337723B/es unknown
- 2009-12-04 EP EP20140195370 patent/EP2865389A1/en not_active Withdrawn
- 2009-12-04 SG SG2012088373A patent/SG186611A1/en unknown
- 2009-12-04 NZ NZ592977A patent/NZ592977A/xx not_active IP Right Cessation
- 2009-12-04 EP EP09793590.2A patent/EP2376108B1/en not_active Not-in-force
- 2009-12-04 NZ NZ604186A patent/NZ604186A/en not_active IP Right Cessation
- 2009-12-04 ES ES09793590.2T patent/ES2622562T3/es active Active
- 2009-12-04 KR KR1020157012347A patent/KR101634058B1/ko not_active Expired - Fee Related
- 2009-12-04 PE PE2011001186A patent/PE20110891A1/es not_active Application Discontinuation
- 2009-12-04 CA CA2744754A patent/CA2744754A1/en not_active Abandoned
- 2009-12-04 CN CN200980149635.5A patent/CN102245198B/zh not_active Expired - Fee Related
- 2009-12-04 PE PE2014000753A patent/PE20142330A1/es not_active Application Discontinuation
- 2009-12-04 DK DK09793590.2T patent/DK2376108T3/en active
- 2009-12-04 KR KR1020117015895A patent/KR101413844B1/ko not_active Expired - Fee Related
- 2009-12-04 MX MX2011006077A patent/MX2011006077A/es active IP Right Grant
- 2009-12-04 AU AU2009325950A patent/AU2009325950B2/en not_active Ceased
- 2009-12-04 SG SG10201400388QA patent/SG10201400388QA/en unknown
- 2009-12-04 JP JP2011540292A patent/JP5209800B2/ja not_active Expired - Fee Related
- 2009-12-04 WO PCT/IB2009/055508 patent/WO2010067286A2/en not_active Ceased
- 2009-12-04 RU RU2011121043/10A patent/RU2495049C2/ru not_active IP Right Cessation
- 2009-12-04 KR KR1020137003578A patent/KR101644221B1/ko not_active Expired - Fee Related
- 2009-12-07 AR ARP090104737A patent/AR074505A1/es unknown
- 2009-12-08 TW TW098141914A patent/TWI387463B/zh not_active IP Right Cessation
- 2009-12-09 US US12/634,336 patent/US8298547B2/en not_active Expired - Fee Related
-
2011
- 2011-05-19 IL IL213029A patent/IL213029A0/en unknown
- 2011-06-01 ZA ZA2011/04072A patent/ZA201104072B/en unknown
- 2011-06-10 CO CO11072267A patent/CO6561830A2/es not_active Application Discontinuation
-
2012
- 2012-08-01 US US13/564,103 patent/US8475801B2/en not_active Expired - Fee Related
- 2012-08-08 JP JP2012175784A patent/JP5367137B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-29 US US13/904,432 patent/US9216229B2/en not_active Expired - Fee Related
- 2013-08-12 JP JP2013167494A patent/JP5964280B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-02 JP JP2016039991A patent/JP2016164156A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004220549B2 (en) | Influenza virus vaccine | |
| JP5654345B2 (ja) | 多量体マルチエピトープインフルエンザワクチン | |
| TWI379839B (en) | Aβ immunogenic peptide carrier conjugates and methods of producing same | |
| JP2016164156A5 (enExample) | ||
| RU2011121043A (ru) | ВАКЦИНА ПРОТИВ ПЕПТИДА CH3 IgE | |
| DK2590675T3 (en) | ANTI-ANTI-COMPOSITIONS AND PROCEDURES FOR RESPIRATORY SYNCYTIAL VIRUS | |
| JP2006504653A5 (enExample) | ||
| CN101932594A (zh) | 可用作疫苗的自装配肽纳米颗粒 | |
| JP2008525423A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| JP2010535025A5 (enExample) | ||
| IL165003A (en) | Ghrelin-carrier conjugates | |
| FI3501534T3 (fi) | Rokotekoostumuksia, jotka käsittävät mutatoitua tekijä h:ta sitovaa proteiinia | |
| JP2014509838A5 (enExample) | ||
| JP2009520758A5 (enExample) | ||
| JP2010532656A5 (enExample) | ||
| JP2011517938A5 (enExample) | ||
| JP2013541528A5 (enExample) | ||
| JP2009500298A5 (enExample) | ||
| JP2006523185A5 (enExample) | ||
| HRP20140886T1 (hr) | MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU | |
| JP2019526261A5 (enExample) | ||
| WO2005117983A3 (en) | Carrier conjugates of tnf-peptides | |
| JP2011514167A5 (enExample) | ||
| ZA200506241B (en) | Influenze virus vaccine |